Skip NavigationSkip to Content
Return Return to Search Results

Phase I and Pharmacology Study of Ropidoxuridine (IPdR) as Prodrug for Iododeoxyuridine-Mediated Tumor Radiosensitization in Advanced GI Cancer Undergoing Radiation

  1. Author:
    Kinsella, Timothy
    Safran, Howard
    Wiersma, Susan
    DiPetrillo, Thomas
    Schumacher, Andrew
    Rosati, Kayla
    Vatkevich, John
    Anderson, Lawrence W.
    Hill,Kimberly
    Kunos, Charles
    Collins,Jerry

  2. Author Address

    Brown Univ, Oncol Grp BrUOG, Providence, RI 02912 USA.EMEK Inc, Warwick, RI USA.Lifespan Canc Inst, Providence, RI USA.NCI, DTP, Bethesda, MD 20892 USA.Leidos Biomed Res Inc, Frederick Natl Lab Canc Res, Frederick, MD USA.NCI, CTEP, Bethesda, MD 20892 USA.
    1. Year: 2019
    2. Date: Oct 15
  2. Journal: CLINICAL CANCER RESEARCH
  3. AMER ASSOC CANCER RESEARCH,
    1. 25
    2. 20
    3. Pages: 6035-6043
  5. Type of Article: Article
  6. ISSN: 1078-0432
  1. Abstract:

    Purpose: Iododeoxyuridine (IUdR) is a potent radiosensitizer; however, its clinical utility is limited by dose-limiting systemic toxicities and the need for prolonged continuous infusion. 5-Iodo-2-pyrimidinone-2'-deoxyribose (IPdR) is an oral prodrug of IUdR that, compared with IUdR, is easier to administer and less toxic, with a more favorable therapeutic index in preclinical studies. Here, we report the clinical and pharmacologic results of a first-in-human phase I dose escalation study of IPdR thorn concurrent radiation therapy (RT) in patients with advanced metastatic gastrointestinal (GI) cancers.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1158/1078-0432.CCR-19-0862
  3. PMID: 31337643
  4. PMCID: PMC6801071
  5. View record in Web of Science®
  6. WOS: 000494361900005

Library Notes

  1. Fiscal Year: FY2019-2020
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel